GlassScriptPhysician profile
William E Tausend
NPI 1134549140
$19,880.35
in general payments reported to CMS, 2019-2025
42 companies · $3,010 in 2025
The $3,010 reported for 2025 was more than what 84% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,777 · 2020: $2,387 · 2021: $2,166 · 2022: $3,121 · 2023: $3,298 · 2024: $3,121 · 2025: $3,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,350 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,349.52 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,128.43 | 2019-2025 | |
| Abbvie INC. | $1,911.55 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $1,879.43 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $1,656.78 | 2020-2025 | Tremfya, Simponi, Stelara |
| Lilly USA, LLC | $1,605.07 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Mayne Pharma Commercial LLC | $1,170.11 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,103.15 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Galderma Laboratories, L.P. | $1,090.77 | 2019-2024 | Oracea, Twyneo, Aklief |
| Regeneron Healthcare Solutions, INC. | $997.69 | 2020-2025 | Dupixent |
| Leo Pharma INC. | $922.33 | 2019-2025 | Adbry |
| Ucb, INC. | $679.07 | 2020-2025 | Bimzelx |
| Dermavant Sciences, INC. | $661.07 | 2022-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $585.44 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $578.62 | 2020-2025 | |
| Amgen INC. | $555.15 | 2020-2025 | Otezla, Otezla |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tausend listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.